Mersana Therapeutics, Inc.
NASDAQ: MRSN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin H. Huber
- Employees
- 102
- Headquarters
- Cambridge, United States
- IPO year
- 2017
- Market cap
- $145.4M
- Website
- https://www.mersana.com
Loading MRSN…
Loading profile data…Frequently asked questions about MRSN
What does Mersana Therapeutics, Inc. (MRSN) do?
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical ev...
Where does MRSN trade?
Mersana Therapeutics, Inc. (MRSN) trades on the NASDAQ Global Select.
What sector is MRSN in?
Mersana Therapeutics, Inc. (MRSN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mersana Therapeutics, Inc.?
Martin H. Huber is the chief executive officer of Mersana Therapeutics, Inc. (MRSN).
Where is Mersana Therapeutics, Inc. headquartered?
Mersana Therapeutics, Inc. is headquartered in United States.
Does MRSN pay a dividend?
Mersana Therapeutics, Inc. (MRSN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MRSN go public?
Mersana Therapeutics, Inc. (MRSN) completed its initial public offering in 2017.